<DOC>
	<DOCNO>NCT00000963</DOCNO>
	<brief_summary>To evaluate effectiveness , safety , tolerance two dos didanosine ( ddI ) treatment child symptomatic HIV disease discontinue zidovudine ( AZT ) intolerance and/or experience progressive disease AZT . The progression immunodeficiency due HIV infection delay use AZT . The benefit AZT adult AIDS severe AIDS-related complex ( ARC ) appear last approximately 12 18 month , time patient progressive deterioration . Recently publish literature describe reduced sensitivity HIV isolate patient prolonged AZT treatment . Although clinical significance unclear , make development new antiretroviral drug important .</brief_summary>
	<brief_title>A Study Dideoxyinosine ( ddI ) HIV-Infected Children Who Have Not Had Success With Zidovudine Who Can Take Zidovudine</brief_title>
	<detailed_description>The progression immunodeficiency due HIV infection delay use AZT . The benefit AZT adult AIDS severe AIDS-related complex ( ARC ) appear last approximately 12 18 month , time patient progressive deterioration . Recently publish literature describe reduced sensitivity HIV isolate patient prolonged AZT treatment . Although clinical significance unclear , make development new antiretroviral drug important . Children show AZT intolerance and/or progressive disease 6 month AZT therapy receive oral ddI 1 2 dos minimum 48 week , 48-week extension . Patients see clinical laboratory evaluation schedule time study . ( Per 5/12/92 amendment , new patient enrol pharmacokinetics study . ) Per 10/31/94 amendment : Patients eligible receive blind study drug additional 8-16 week final on-study visit , later 2/15/95 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis treatment Pneumocystis carinii pneumonia ( PCP ) . Immunoglobulin . Maintenance therapy amphotericin B ( l mg/kg ) 5 days/week . Concurrent Treatment : Allowed : Blood transfusion . Prior Medication : Allowed : Prophylaxis treatment Pneumocystis carinii pneumonia ( PCP ) . Patients enrol ACTG 128 ACTG 138 must meet study end point meet protocol definition permanently zidovudine ( AZT ) enrol study . Patients currently enrol ACTG 051 reach study end point meet entry criterion ACTG 144 may coenrolled ACTG 144 . Patient guardian available give write informed consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude . Hypersensitivity didanosine ( ddI ) . Symptomatic cardiomyopathy . Seizures well control ongoing anticonvulsant therapy . Symptomatic pancreatitis . Grade 1 high peripheral neuropathy . Active malignancy require chemotherapy . Concurrent Medication : Excluded : Zidovudine ( AZT ) , antiretroviral agent , biological modifier , investigational medication . Avoid : Drugs potential cause peripheral neuropathy pancreatitis . Patients follow exclude : Active malignancy require concomitant chemotherapy . Prior Medication : Excluded : Antiretroviral agent zidovudine ( AZT ) dideoxycytidine ( ddC ) within 4 week study entry . Immunomodulating agent interferon , isoprinosine , interleukin2 within 2 week entry . Any experimental therapy within 1 week entry . Drugs cause prolong neutropenia , significant pancreatitis , significant nephrotoxicity , peripheral neuropathy within 1 week entry .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>